Results 191 to 198 of about 2,262 (198)

A rugged and accurate liquid chromatography–tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013
Long Yuan, Mark E Arnold, Hao Jiang
exaly  

Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma

Journal of Pharmaceutical and Biomedical Analysis, 2015
Hamza Kandoussi, John Ryan, Mark E Arnold   +2 more
exaly  

Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions

Internal Medicine, 2016
Yuichi Honma, Masaru Harada, Shinji Oe   +2 more
exaly  

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction

Journal of Medical Virology, 2017
Masataka Tsuge, Takashi Nakahara, Michio Imamura   +2 more
exaly  

New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir

Journal of Gastroenterology, 2017
Seiichi Mawatari, Kotaro Kumagai, Sho Ijūin   +2 more
exaly  

Asunaprevir/beclabuvir/daclatasvir

Reactions Weekly, 2018
openaire   +1 more source

Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir

Clinical Case Reports (discontinued), 2016
exaly  

Asunaprevir/daclatasvir/tacrolimus

Reactions Weekly, 2016
openaire   +1 more source